Tag Archives: FOMX

Top 5 Undervalued Stocks To Invest In Right Now

Uber has agreed to pay 56 current and former employees about $33,900 each, or $1.9 million, to settle their claims of gender discrimination, harassment and hostile work environment.

On Monday, lawyers for the plaintiffs filed paperwork in a Northern California district court that outlined how much the $10 million settlement, announced in April, would go to the current and former staffers involved in the suit.

The lawsuit was filed against Uber in October 2017 by three Latina engineers who alleged they were paid less than their white or Asian male colleagues. The women claimed Uber used a discriminatory “stack ranking” system, alleging “female employees and employees of color are systematically undervalued … because [they] receive, on average, lower rankings despite equal or better performance.”

Those stack rankings were then used, in part, to determine promotions, according to the lawsuit. Uber also set employee pay based on their past compensation, which inherently disadvantages women.

Top 5 Undervalued Stocks To Invest In Right Now: Foamix Pharmaceuticals Ltd.(FOMX)

Advisors’ Opinion:

  • [By Max Byerly]

    HC Wainwright set a $11.00 price target on Foamix Pharmaceuticals (NASDAQ:FOMX) in a research note released on Tuesday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

  • [By Stephan Byrd]

    Press coverage about Foamix Pharmaceuticals (NASDAQ:FOMX) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Foamix Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 45.4298608245084 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

  • [By Joseph Griffin]

    Headlines about Foamix Pharmaceuticals (NASDAQ:FOMX) have been trending somewhat positive recently, according to Accern. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Foamix Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 47.5479155329096 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

  • [By Ethan Ryder]

    News headlines about Foamix Pharmaceuticals (NASDAQ:FOMX) have trended somewhat positive recently, Accern reports. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Foamix Pharmaceuticals earned a news impact score of 0.15 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 48.1562748121044 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Top 5 Undervalued Stocks To Invest In Right Now: The Gabelli Healthcare & Wellness Trust(GRX)

Advisors’ Opinion:

  • [By Shane Hupp]

    GOLD Reward Token (CURRENCY:GRX) traded 2% higher against the US dollar during the twenty-four hour period ending at 12:00 PM ET on July 22nd. GOLD Reward Token has a market capitalization of $0.00 and $0.00 worth of GOLD Reward Token was traded on exchanges in the last 24 hours. One GOLD Reward Token token can now be bought for about $0.0041 or 0.00000055 BTC on cryptocurrency exchanges including Livecoin and CoinExchange. Over the last week, GOLD Reward Token has traded down 10.8% against the US dollar.

  • [By Stephan Byrd]

    GOLD Reward Token (CURRENCY:GRX) traded flat against the US dollar during the 24-hour period ending at 23:00 PM ET on June 25th. In the last seven days, GOLD Reward Token has traded 2.6% lower against the US dollar. One GOLD Reward Token token can now be bought for approximately $0.0050 or 0.00000080 BTC on popular cryptocurrency exchanges including Livecoin and CoinExchange. GOLD Reward Token has a market cap of $0.00 and $3.00 worth of GOLD Reward Token was traded on exchanges in the last 24 hours.

  • [By Max Byerly]

    Headlines about Gabelli Healthcare & WellnessRx Trust Closed-Ended Fund (NYSE:GRX) have been trending positive on Monday, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Gabelli Healthcare & WellnessRx Trust Closed-Ended Fund earned a coverage optimism score of 0.38 on Accern’s scale. Accern also assigned news articles about the investment management company an impact score of 45.0228414962591 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

  • [By Stephan Byrd]

    GOLD Reward Token (CURRENCY:GRX) traded down 3% against the U.S. dollar during the 1 day period ending at 13:00 PM ET on July 1st. During the last week, GOLD Reward Token has traded flat against the U.S. dollar. One GOLD Reward Token token can currently be purchased for $0.0044 or 0.00000070 BTC on popular exchanges including CoinExchange and Livecoin. GOLD Reward Token has a total market capitalization of $0.00 and approximately $1.00 worth of GOLD Reward Token was traded on exchanges in the last 24 hours.

Top 5 Undervalued Stocks To Invest In Right Now: CNB Financial Corporation(CCNE)

Advisors’ Opinion:

  • [By Max Byerly]

    BidaskClub upgraded shares of CNB Financial (NASDAQ:CCNE) from a hold rating to a buy rating in a research note released on Wednesday morning.

    Several other equities research analysts have also issued reports on CCNE. Boenning Scattergood reissued a buy rating and set a $29.50 price target on shares of CNB Financial in a research report on Monday, February 5th. Zacks Investment Research lowered CNB Financial from a buy rating to a sell rating in a research report on Tuesday, February 20th. ValuEngine raised CNB Financial from a buy rating to a strong-buy rating in a research report on Monday, April 2nd. Finally, Keefe, Bruyette & Woods initiated coverage on CNB Financial in a research report on Tuesday, April 10th. They set a market perform rating and a $35.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The stock presently has an average rating of Hold and an average target price of $31.50.

  • [By Ethan Ryder]

    CNB Financial (NASDAQ:CCNE) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Friday.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on CNB Financial (CCNE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Undervalued Stocks To Invest In Right Now: Old National Bancorp Capital Trust I(ONB)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Old National Bancorp (ONB)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Bank of New York Mellon Corp lifted its stake in shares of Old National Bancorp (NASDAQ:ONB) by 1.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,451,745 shares of the bank’s stock after buying an additional 57,759 shares during the quarter. Bank of New York Mellon Corp’s holdings in Old National Bancorp were worth $64,203,000 at the end of the most recent reporting period.

  • [By Max Byerly]

    Russell Investments Group Ltd. reduced its holdings in shares of Old National Bancorp (NASDAQ:ONB) by 31.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 441,479 shares of the bank’s stock after selling 198,314 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.29% of Old National Bancorp worth $7,461,000 as of its most recent filing with the SEC.

  • [By Shane Hupp]

    SG Americas Securities LLC grew its position in Old National Bancorp (NASDAQ:ONB) by 122.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 150,316 shares of the bank’s stock after buying an additional 82,641 shares during the period. SG Americas Securities LLC’s holdings in Old National Bancorp were worth $2,796,000 at the end of the most recent quarter.

Top 5 Undervalued Stocks To Invest In Right Now: Delaware Enhanced Global Dividend(DEX)

Advisors’ Opinion:

  • [By Max Byerly]

    DEX (CURRENCY:DEX) traded 17.7% lower against the U.S. dollar during the 1-day period ending at 19:00 PM E.T. on February 16th. One DEX token can currently be purchased for $0.0382 or 0.00001051 BTC on popular cryptocurrency exchanges including IDAX and Coinbit. DEX has a market cap of $7.31 million and $2.95 million worth of DEX was traded on exchanges in the last day. Over the last week, DEX has traded 28.8% lower against the U.S. dollar.

Best Value Stocks To Invest In Right Now

Australian hospital operator Healthscope Ltd. said two competing takeover bids both undervalue the company and it won’t open its books to either suitor.

Instead, Healthscope said Tuesday it was exploring whether to sell and lease back any of its 29 freehold properties, which have a book value of about A$1.3 billion ($986 million).

Canada’s Brookfield Asset Management Inc. last week offered A$4.35 billion, or A$2.50 a share, in cash for Healthscope, topping a bid from private equity firm BGH Capital. Shares in the Melbourne-based company tumbled 5.3 percent to A$2.33 at 10:23 a.m. in Sydney.

For more details on Healthscope’s announcement, click here

In a separate statement Tuesday, Healthscope said it now expected hospital operating Ebitda in the 2018 financial year to be between A$340 million and A$345 million. The company had previously expected it to be in line with last year’s A$359.4 million.

Best Value Stocks To Invest In Right Now: Laboratory Corporation of America Holdings(LH)

Advisors’ Opinion:

  • [By Shane Hupp]

    These are some of the headlines that may have impacted Accern’s analysis:

    Get LabCorp alerts:

    $2.92 Earnings Per Share Expected for LabCorp (LH) This Quarter (americanbankingnews.com) Global Contract Research Organization Market 2018 Pioneers by 2023: Parexel, LabCorp (Covance), PRA, PPD … (theexpertconsulting.com) OmniSeq and LabCorp Launch OmniSeq Advance? Assay (nasdaq.com) LabCorp’s latest collaboration aims to accelerate personalized, genomic medicine (bizjournals.com) Can Laboratory Corporation of America Holdings (NYSE:LH) Continue To Outperform Its Industry? (finance.yahoo.com)

    LH has been the topic of several analyst reports. Barclays lifted their target price on shares of LabCorp from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Monday, February 26th. They noted that the move was a valuation call. Zacks Investment Research raised shares of LabCorp from a “hold” rating to a “buy” rating and set a $190.00 target price on the stock in a research note on Friday, February 9th. Jefferies Group reaffirmed a “hold” rating and issued a $176.00 target price on shares of LabCorp in a research note on Tuesday, March 6th. ValuEngine raised shares of LabCorp from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Finally, Morgan Stanley lifted their target price on shares of LabCorp from $182.00 to $192.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 28th. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. LabCorp has an average rating of “Buy” and an average target price of $191.06.

  • [By Keith Speights, Chuck Saletta, and Brian Feroldi]

    We posed that question to three Motley Fool contributors. Here’s why they picked Abiomed (NASDAQ:ABMD), Laboratory Corporation of America (NYSE:LH), and Vertex Pharmaceuticals (NASDAQ:VRTX) as top healthcare stocks to buy in September.

  • [By Joseph Griffin]

    Envestnet Asset Management Inc. reduced its position in shares of LabCorp (NYSE:LH) by 45.1% during the first quarter, HoldingsChannel.com reports. The fund owned 19,179 shares of the medical research company’s stock after selling 15,727 shares during the quarter. Envestnet Asset Management Inc.’s holdings in LabCorp were worth $3,116,000 at the end of the most recent reporting period.

  • [By Joseph Griffin]

    Renaissance Technologies LLC trimmed its position in Laboratory Corp. of America Holdings (NYSE:LH) by 39.0% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 556,105 shares of the medical research company’s stock after selling 355,300 shares during the period. Renaissance Technologies LLC owned about 0.55% of Laboratory Corp. of America worth $99,838,000 as of its most recent filing with the SEC.

Best Value Stocks To Invest In Right Now: Foamix Pharmaceuticals Ltd.(FOMX)

Advisors’ Opinion:

  • [By Chris Lange]

    Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) shares were last seen up early on Wednesday after the company announced a solid performance in its late-stage trial for moderate-to-severe acne.

  • [By Ethan Ryder]

    News headlines about Foamix Pharmaceuticals (NASDAQ:FOMX) have trended somewhat positive recently, Accern reports. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Foamix Pharmaceuticals earned a news impact score of 0.15 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 48.1562748121044 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

  • [By Joseph Griffin]

    Foamix Pharmaceuticals (NASDAQ:FOMX)‘s stock had its “buy” rating reiterated by HC Wainwright in a report issued on Wednesday, MarketBeat reports. They currently have a $14.00 price objective on the specialty pharmaceutical company’s stock, up from their prior price objective of $12.00. HC Wainwright’s price objective would indicate a potential upside of 122.22% from the stock’s current price.

  • [By Stephan Byrd]

    Press coverage about Foamix Pharmaceuticals (NASDAQ:FOMX) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Foamix Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 45.4298608245084 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

  • [By Max Byerly]

    HC Wainwright set a $11.00 price target on Foamix Pharmaceuticals (NASDAQ:FOMX) in a research note released on Tuesday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

  • [By Joseph Griffin]

    Headlines about Foamix Pharmaceuticals (NASDAQ:FOMX) have been trending somewhat positive recently, according to Accern. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Foamix Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 47.5479155329096 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Best Value Stocks To Invest In Right Now: Nordson Corporation(NDSN)

Advisors’ Opinion:

  • [By Steve Symington]

    Nordson Corporation (NASDAQ:NDSN) announced solid fiscal second-quarter 2018 results on Monday after the market closed, including an expected decline in organic volume that was more than offset by acquisitive growth.

  • [By Ethan Ryder]

    Here are some of the news stories that may have effected Accern’s analysis:

    Get Nordson alerts:

    FY2019 EPS Estimates for Nordson Co. (NDSN) Raised by Analyst (americanbankingnews.com) Research Analysts Issue Forecasts for Nordson Co.’s Q1 2019 Earnings (NDSN) (americanbankingnews.com) Nordson Co. to Post Q1 2019 Earnings of $1.17 Per Share, Seaport Global Securities Forecasts (NDSN) (americanbankingnews.com) Here’s Why You Must Hold on to Nordson (NDSN) Stock for Now (finance.yahoo.com) Here's Why You Must Hold on to Nordson (NDSN) Stock for Now (finance.yahoo.com)

    Shares of Nordson stock opened at $135.89 on Monday. The firm has a market capitalization of $7.89 billion, a P/E ratio of 25.31, a PEG ratio of 1.74 and a beta of 1.29. Nordson has a twelve month low of $107.16 and a twelve month high of $151.84. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.31 and a current ratio of 3.16.

  • [By Motley Fool Staff]

    Nordson (NASDAQ:NDSN) Q2 2018 Earnings Conference CallMay. 22, 2018 8:30 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Best Value Stocks To Invest In Right Now: Netflix, Inc.(NFLX)

Advisors’ Opinion:

  • [By Chris Hill]

    Hill: It’s interesting, I saw a couple of comments from the executives, I believe this was from the call. One of the things that AMC, and networks in its category, is trying to do to stem the tide of Netflix (NASDAQ:NFLX) is to talk up not only the quality of their programming, but also their ability to promote those shows. And I think there’s a little something to that. I don’t know, from an investor’s standpoint … I think that matters more on the content creator side of thing as opposed to investors. If you’re an investor and you’re looking at Netflix and AMC and just look at the past few years, it’s kind of easy to figure out which one has been the better investment. 

  • [By Rick Munarriz]

    It’s been a notable week, with Netflix (NASDAQ:NFLX) picking up the pace in the market cap race. The world’s leading premium streaming service surpassed Comcast (NASDAQ:CMCSA) in terms of market capitalization on Wednesday. A day later it was muscling ahead of Disney (NYSE:DIS) to command the largest market cap among media companies. 

  • [By Garrett Baldwin]

    We’re about to reveal a little wealth secret that could unlock the trade of a lifetime. Money Morning Special Situation Strategist Tim Melvin takes you inside what could easily be a 10-bagger for investors in the weeks ahead. Read more right here.

    The Top Stock Market Stories for Friday
    Meanwhile, the United States will continue to meet with China to discuss ways to accelerate a deal between the two nations on trade. U.S. Commerce head Wilbur Ross will be visiting the nation next month to lead the next round of talks. Last weekend, the two nations agreed in principle to avoid a trade war. Here’s the thing… the U.S. government doesn’t want you to know the full story of what is happening. Here’s a look at the backroom details…. U.S. crude oil prices slumped below $70 per barrel Friday thanks to reports out of Russia on its plans to hike production. Russia says it may increase production as part of a plan to ease portions of its deal with OPEC to cap excessive global output. Oil traders have long suspected that Russia would be one of the first countries to turn away from the ongoing deal with Saudi Arabia and the rest of the global oil cartel as soon as prices and inventory levels stabilized. This could be a blow to predictions among OPEC nations, as well as some traders who were hoping that oil could push back toward $100 per barrel.
    Three Stocks to Watch Today: FL, NFLX, AMZN
    Foot Locker Inc. (NYSE: FL) leads a light day of earnings reports. Shares of the shoe retailer popped 13% after the firm reported earnings per share (EPS) of $1.45. Wall Street had anticipated EPS of just $1.24. The retailer benefited from stronger same-store sales and higher revenue, which also beat Wall Street expectations. On Thursday, Netflix Inc. (Nasdaq: NFLX) surpassed The Walt Disney Co. (NYSE: DIS) in market capitalization to become the most valuable media property on the planet. It’s worth noting, however, that Netflix’s market capitalization of $163 billion

Best Value Stocks To Invest In Right Now: First Bancorp(FBNC)

Advisors’ Opinion:

  • [By Stephan Byrd]

    First Bancorp (NASDAQ:FBNC) has been assigned a consensus recommendation of “Buy” from the seven brokerages that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $41.50.

  • [By Ethan Ryder]

    First Bancorp (NASDAQ:FBNC) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday.

  • [By Joseph Griffin]

    First Bancorp (NASDAQ:FBNC)‘s stock had its “buy” rating reaffirmed by analysts at Brean Capital in a note issued to investors on Monday.

  • [By Logan Wallace]

    First Bancorp (NASDAQ:FBNC) CEO Richard H. Moore purchased 1,250 shares of First Bancorp stock in a transaction dated Wednesday, September 19th. The shares were purchased at an average cost of $39.79 per share, with a total value of $49,737.50. Following the acquisition, the chief executive officer now owns 139,935 shares of the company’s stock, valued at approximately $5,568,013.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on First Bancorp (FBNC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    First Bancorp (NASDAQ:FBNC) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Monday.

Best Value Stocks To Invest In Right Now: ChannelAdvisor Corporation(ECOM )

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on ChannelAdvisor (ECOM)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Omnitude (CURRENCY:ECOM) traded up 2.1% against the U.S. dollar during the 24 hour period ending at 15:00 PM ET on September 14th. One Omnitude token can now be purchased for about $0.0736 or 0.00001135 BTC on cryptocurrency exchanges including IDEX and BitForex. During the last seven days, Omnitude has traded down 17.1% against the U.S. dollar. Omnitude has a market cap of $3.57 million and approximately $208,719.00 worth of Omnitude was traded on exchanges in the last 24 hours.

  • [By Stephan Byrd]

    Omnitude (CURRENCY:ECOM) traded 4.3% higher against the US dollar during the twenty-four hour period ending at 20:00 PM ET on September 20th. Over the last seven days, Omnitude has traded 2.6% lower against the US dollar. Omnitude has a total market cap of $3.44 million and $203,696.00 worth of Omnitude was traded on exchanges in the last 24 hours. One Omnitude token can currently be bought for $0.0708 or 0.00001088 BTC on popular cryptocurrency exchanges including BitForex and IDEX.

  • [By Logan Wallace]

    Omnitude (CURRENCY:ECOM) traded 7.4% lower against the US dollar during the 24-hour period ending at 19:00 PM E.T. on September 16th. During the last seven days, Omnitude has traded down 19.9% against the US dollar. Omnitude has a total market capitalization of $3.26 million and $257,091.00 worth of Omnitude was traded on exchanges in the last day. One Omnitude token can now be bought for about $0.0672 or 0.00001032 BTC on cryptocurrency exchanges including IDEX and BitForex.